

Pure Ceylon Cinnamon Nutraceutical Capsule







Clinical & Health Supplement Data



Manufacturing Process

Organically cultivated Pure Ceylon Cinnamon is obtained from its native regions in Southern Sri Lanka and the outer bark of the cinnamon stem is obtained through the traditional authentic peeling process used for many centuries by cinnamon peeling communities in ancient Ceylon.

After withering, the outer bark is subject to hydro distillation, and cinnamon bark oil is removed. The remaining hydro-distillate is refluxed at 100°C for 1h and the water extract is obtained in a GMP certified multipurpose extraction facility.

The water in the hot water extract is then slowly removed under vacuum and lyophilized to obtain dry crude tannin-rich cinnamon extract and is capsuled for nutraceutical purposes using a tailormade capsule formula¹ rich in Insulin-mimetic Procyanidins.^{2,3}

Cinnamon Procyanidins

Dosage

Each 500mg capsule contains: Standardized Cinnamomum zeylanicum extract

Sodium stearate Magnesium silicate

Plant gelatin

Recommended Dose: Two 500mg capsules per day

Clinical Observations^{4,5,6,7,8}

∞ Reduces HbA1c

∞ Reduces Total Cholesterol

∞ Reduces LDL Cholesterol

∞ Maintain Healthy HDL Cholesterol

∞ Liver and Kidney functions remain normal



Results of Clinical Trial Phase II/III⁴

$\underline{\textbf{Cinnamon phase II/III clinical trial-Glycaemic control in the cinnamon and placebo groups}\\$

			Mean (±SD)		
	Visit 0	Visit 1	Visit 2	Visit 3	Visit 4
	(Baseline)(n=210)	(1 month)(n=199)	(2 months)(n=195)	(3 months)(n=188)	(4 months)(n=186)
Fasting Plasma Glucose (mg/dl)					
Placebo	129.5 (±50.6)	127.4 (±53.4)	128.3 (±40.3)	128.6 (±51.1)	130.4 (±52.2)
Cinnamon 250	136.3 (±56.9)*#	137.6 (±52.4)	132.8 (±55.5)	119.9 (±44.9)*	121.8 (±48.4)#
Cinnamon 500	136.5 (±54.8)*#	131.1 (±50.1)	131.5 (±57.1)	121.5 (±40.5)*	120.2 (±45.2)#
HbA1c (%)					
Placebo	8.0 (±1.7)	NM	8.1(±1.8)	NM	8.2 (±1.9)
Cinnamon 250	$8.2 (\pm 1.8)^*$	NM	7.9 (±1.9)	NM	7.7 (±1.7)*
Cinnamon 500	8.7 (±1.8)*#	NM	8.1 (±1.7)#	NM	7.9 (±1.7)*

^{*#} Values in a single row with same superscript are significantly different from each other; NM – Not Measured; SD – Standard Deviation

Cinnamon phase II/III clinical trial - changes in cholesterol and triglycerides

Total cholesterol (mg/dl) Placebo 185.4 (±49.1) NM 178.8 (±48.1) NM 181.8 (±48.6) Cinnamon 250 167.7 (±40.1) NM 170.3 (±39.4) NM 172.3 (±44.6) Cinnamon 500 178.9 (±39.1)* NM 174.1 (±45.3) NM 164.7 (37.7)* LDL cholesterol (mg/dl) Placebo 109.0 (±42.1) NM 105.4 (±43.4) NM 103.1 (±31.8) Cinnamon 250 97.6 (±36.3) NM 105.7 (±41.1) NM 101.4 (±32.9) Cinnamon 500 106.1 (±35.7)* NM 100.8 (±38.6) NM 96.1 (±28.5)* HDL cholesterol (mg/dl) Placebo 49.7 (±12.2) NM 47.7 (±11.4) NM 49.1 (±12.1) Cinnamon 250 47.2 (±11.9) NM 46.4 (±13.1) NM 47.5 (±11.3) Cinnamon 500 48.9 (±11.8) NM 46.4 (±13.1) NM 47.5 (±11.3)		Mean (±SD)						
Total cholesterol (mg/dl) Placebo 185.4 (±49.1) NM 178.8 (±48.1) NM 181.8 (±48.6) Cinnamon 250 167.7 (±40.1) NM 170.3 (±39.4) NM 172.3 (±44.6) Cinnamon 500 178.9 (±39.1)* NM 174.1 (±45.3) NM 164.7 (37.7)* LDL cholesterol (mg/dl) Placebo 109.0 (±42.1) NM 105.4 (±43.4) NM 103.1 (±31.8) Cinnamon 250 97.6 (±36.3) NM 105.7 (±41.1) NM 101.4 (±32.9) Cinnamon 500 106.1 (±35.7)* NM 100.8 (±38.6) NM 96.1 (±28.5)* HDL cholesterol (mg/dl) Placebo 49.7 (±12.2) NM 47.7 (±11.4) NM 49.1 (±12.1) Cinnamon 250 47.2 (±11.9) NM 46.4 (±13.1) NM 47.5 (±11.3) Cinnamon 500 48.9 (±11.8) NM 46.4 (±13.1) NM 47.5 (±11.3) Triglycerides (mg/dl) Placebo 124.4 (±60.2) NM 128.2 (±54.0) NM 122.1 (±42.6) Cinnamon 250 117.4 (±44.8) NM 114.4 (±39.6) NM 120.4 (±57.7)		Visit 0	Visit 1	Visit 2	Visit 3	Visit 4		
Placebo 185.4 (±49.1) NM 178.8 (±48.1) NM 181.8 (±48.6) Cinnamon 250 167.7 (±40.1) NM 170.3 (±39.4) NM 172.3 (±44.6) Cinnamon 500 178.9 (±39.1)* NM 174.1 (±45.3) NM 164.7 (37.7)* LDL cholesterol (mg/dl) Placebo 109.0 (±42.1) NM 105.4 (±43.4) NM 103.1 (±31.8) Cinnamon 250 97.6 (±36.3) NM 105.7 (±41.1) NM 101.4 (±32.9) Cinnamon 500 106.1 (±35.7)* NM 100.8 (±38.6) NM 96.1 (±28.5)* HDL cholesterol (mg/dl) Placebo 49.7 (±12.2) NM 47.7 (±11.4) NM 49.1 (±12.1) Cinnamon 250 47.2 (±11.9) NM 46.4 (±13.1) NM 47.5 (±11.3) Cinnamon 500 48.9 (±11.8) NM 46.4 (±13.1) NM 47.5 (±11.3) Triglycerides (mg/dl) Placebo 124.4 (±60.2) NM 128.2 (±54.0) NM 122.1 (±42.6) Cinnamon 250 117.4 (±44.8) NM 114.4 (±39.6) NM 120.4 (±57.7)		(Baseline)(n=210)	(1 month)(n=199)	(2 months)(n=195)	(3 months)(n=188)	(4 months)(n=186)		
Cinnamon 250	Total cholesterol (mg/dl)							
Cinnamon 500 178.9 (±39.1)* NM 174.1 (±45.3) NM 164.7 (37.7)* LDL cholesterol (mg/dl) Placebo 109.0 (±42.1) NM 105.4 (±43.4) NM 103.1 (±31.8) Cinnamon 250 97.6 (±36.3) NM 105.7 (±41.1) NM 101.4 (±32.9) Cinnamon 500 106.1 (±35.7)* NM 100.8 (±38.6) NM 96.1 (±28.5)* HDL cholesterol (mg/dl) Placebo 49.7 (±12.2) NM 47.7 (±11.4) NM 49.1 (±12.1) Cinnamon 250 47.2 (±11.9) NM 46.4 (±13.1) NM 47.5 (±11.3) Cinnamon 500 48.9 (±11.8) NM 46.4 (±13.1) NM 47.5 (±11.3) Triglycerides (mg/dl) Placebo 124.4 (±60.2) NM 128.2 (±54.0) NM 122.1 (±42.6) Cinnamon 250 117.4 (±44.8) NM 114.4 (±39.6) NM 120.4 (±57.7)	Placebo	185.4 (±49.1)	NM	178.8 (±48.1)	NM	181.8 (±48.6)		
Description Description	Cinnamon 250	167.7 (±40.1)	NM	170.3 (±39.4)	NM	172.3 (±44.6)		
Placebo 109.0 (±42.1) NM 105.4 (±43.4) NM 103.1 (±31.8) Cinnamon 250 97.6 (±36.3) NM 105.7 (±41.1) NM 101.4 (±32.9) Cinnamon 500 106.1 (±35.7)* NM 100.8 (±38.6) NM 96.1 (±28.5)* HDL cholesterol (mg/dl) Placebo 49.7 (±12.2) NM 47.7 (±11.4) NM 49.1 (±12.1) Cinnamon 250 47.2 (±11.9) NM 46.4 (±13.1) NM 47.5 (±11.3) Cinnamon 500 48.9 (±11.8) NM 46.4 (±13.1) NM 47.5 (±11.3) Triglycerides (mg/dl) Placebo 124.4 (±60.2) NM 128.2 (±54.0) NM 122.1 (±42.6) Cinnamon 250 NM 120.4 (±457.7)	Cinnamon 500	178.9 (±39.1)*	NM	174.1 (±45.3)	NM	164.7 (37.7)*		
Cinnamon 250 97.6 (±36.3) NM 105.7 (±41.1) NM 101.4 (±32.9) Cinnamon 500 106.1 (±35.7)* NM 100.8 (±38.6) NM 96.1 (±28.5)* HDL cholesterol (mg/dl) Placebo 49.7 (±12.2) NM 47.7 (±11.4) NM 49.1 (±12.1) Cinnamon 250 47.2 (±11.9) NM 46.4 (±13.1) NM 47.5 (±11.3) Cinnamon 500 48.9 (±11.8) NM 46.4 (±13.1) NM 47.5 (±11.3) Triglycerides (mg/dl) Placebo 124.4 (±60.2) NM 128.2 (±54.0) NM 122.1 (±42.6) Cinnamon 250 117.4 (±44.8) NM 114.4 (±39.6) NM 120.4 (±57.7)	LDL cholesterol (mg/dl)							
Cinnamon 500 106.1 (±35.7)* NM 100.8 (±38.6) NM 96.1 (±28.5)* HDL cholesterol (mg/dl) Placebo 49.7 (±12.2) NM 47.7 (±11.4) NM 49.1 (±12.1) Cinnamon 250 47.2 (±11.9) NM 46.4 (±13.1) NM 47.5 (±11.3) Cinnamon 500 48.9 (±11.8) NM 46.4 (±13.1) NM 47.5 (±11.3) Triglycerides (mg/dl) Placebo 124.4 (±60.2) NM 128.2 (±54.0) NM 122.1 (±42.6) Cinnamon 250 117.4 (±44.8) NM 114.4 (±39.6) NM 120.4 (±57.7)	Placebo	109.0 (±42.1)	NM	105.4 (±43.4)	NM	103.1 (±31.8)		
HDL cholesterol (mg/dl) Placebo 49.7 (±12.2) NM 47.7 (±11.4) NM 49.1 (±12.1) Cinnamon 250 47.2 (±11.9) NM 46.4 (±13.1) NM 47.5 (±11.3) Cinnamon 500 48.9 (±11.8) NM 46.4 (±13.1) NM 47.5 (±11.3) Triglycerides (mg/dl) Placebo 124.4 (±60.2) NM 128.2 (±54.0) NM 122.1 (±42.6) Cinnamon 250 117.4 (±44.8) NM 114.4 (±39.6) NM 120.4 (±57.7)	Cinnamon 250	97.6 (±36.3)	NM	105.7 (±41.1)	NM	101.4 (±32.9)		
Placebo 49.7 (±12.2) NM 47.7 (±11.4) NM 49.1 (±12.1) Cinnamon 250 47.2 (±11.9) NM 46.4 (±13.1) NM 47.5 (±11.3) Cinnamon 500 48.9 (±11.8) NM 46.4 (±13.1) NM 47.5 (±11.3) Triglycerides (mg/dl) Placebo 124.4 (±60.2) NM 128.2 (±54.0) NM 122.1 (±42.6) Cinnamon 250 117.4 (±44.8) NM 114.4 (±39.6) NM 120.4 (±57.7)	Cinnamon 500	106.1 (±35.7)*	NM	100.8 (±38.6)	NM	96.1 (±28.5)*		
Cinnamon 250 47.2 (±11.9) NM 46.4 (±13.1) NM 47.5 (±11.3) Cinnamon 500 48.9 (±11.8) NM 46.4 (±13.1) NM 47.5 (±11.3) Triglycerides (mg/dl) Placebo 124.4 (±60.2) NM 128.2 (±54.0) NM 122.1 (±42.6) Cinnamon 250 117.4 (±44.8) NM 114.4 (±39.6) NM 120.4 (±57.7)	HDL cholesterol (mg/dl)							
Cinnamon 500 48.9 (±11.8) NM 46.4 (±13.1) NM 47.5 (±11.3) Triglycerides (mg/dl) Placebo 124.4 (±60.2) NM 128.2 (±54.0) NM 122.1 (±42.6) Cinnamon 250 117.4 (±44.8) NM 114.4 (±39.6) NM 120.4 (±57.7)	Placebo	49.7 (±12.2)	NM	47.7 (±11.4)	NM	49.1 (±12.1)		
Triglycerides (mg/dl) Placebo 124.4 (±60.2) NM 128.2 (±54.0) NM 122.1 (±42.6) Cinnamon 250 117.4 (±44.8) NM 114.4 (±39.6) NM 120.4 (±57.7)	Cinnamon 250	47.2 (±11.9)	NM	46.4 (±13.1)	NM	47.5 (±11.3)		
Placebo 124.4 (±60.2) NM 128.2 (±54.0) NM 122.1 (±42.6) Cinnamon 250 117.4 (±44.8) NM 114.4 (±39.6) NM 120.4 (±57.7)	Cinnamon 500	48.9 (±11.8)	NM	46.4 (±13.1)	NM	47.5 (±11.3)		
Cinnamon 250 117.4 (±44.8) NM 114.4 (±39.6) NM 120.4 (±57.7)	Triglycerides (mg/dl)							
	Placebo	124.4 (±60.2)	NM	128.2 (±54.0)	NM	122.1 (±42.6)		
Cinnamon 500 117.1 (±52.0) NM 114.3 (±41.8) NM 117.6 (±53.8)	Cinnamon 250	117.4 (±44.8)	NM	114.4 (±39.6)	NM	120.4 (±57.7)		
	Cinnamon 500	117.1 (±52.0)	NM	114.3 (±41.8)	NM	117.6 (±53.8)		

^{*#} Values in a single row with same superscript are significantly different from each other; HDL – High Density Lipoprotein; LDL – Low Density Lipoprotein; NM – Not Measured; SD – Standard Deviation



Reference

- 1. Ceylon cinnamon (*Cinnamomum zeylanicum*) capsule for reducing cholesterol and blood pressure. Date Gazette: 22.01.2021. Patent No: 19248. International Patent Classification: A61K 36/54 A61K 36/48.
- Paranagama P.A., Dayananda K.R. & Jinasena W. Hewage. (2020). Chemistry and Bioactive Compounds of Cinnamomum zeylanicum Blume. In Cinnamon Botany, Agronomy, Chemistry, and Industrial Applications. (Eds. Ranjith Senaratne & Ranjith Pathirana). 1-38pp Springer, Switzerland. PP 1-38. https://doi.org/10.1007/978-3-030-54426-3 10.
- 3. Abeysekera W.P.K.M. (2018). Assessment of some potential health benefits of Sri Lankan cinnamon, *Cinnamomum zeylanicum* Blume (*Cinnamomum verum* Presl) by studying selected bioactivities. PhD Thesis, Faculty of Science, University of Colombo, Sri Lanka.
- 4. Ranasinghe P. (2018). Evaluation of Zinc supplementation in prevention and Ceylon cinnamon in treatment of Diabetes Mellitus. PhD Thesis, Faculty of Medicine, University of Colombo, Sri Lanka.
- 5. Khan A., Safdar M., Khan M.M.A., Khattak K. N. & Anderson R. A. (2003). Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care, 26, 3215-8. DOI: 10.2337/diacare.26.12.3215.
- Ranasinghe P., Jayawardena R., Pigera S., Wathurapatha W.S., Weeratunga H.D, Premakumara G.A.S., Katulanda P., Constantine G.R. & Galappaththy P. (2017). Evaluation of pharmacodynamic properties and safety of Cinnamomum zeylanicum (Ceylon cinnamon) in healthy adults: a phase I clinical trial. BMC Complementary and Alternative Medicine (2017) 17:550. https://doi.org/10.1186/s12906-017-2067-7.
- 7. Premakumara G.A.S., Abeysekera W.P.K.M. & Ratnasooriya W.D. (2017). Antiamylase, Anticholinesterases, Antiglycation, and Glycation Reversing Potential of Bark and Leaf of Ceylon Cinnamon (Cinnamomum zeylanicum Blume) In Vitro. Evidence-Based Complementary and Alternative Medicine, Article ID 5076029, 13 pages. https://doi.org/10.1155/2017/5076029.
- 8. Premakumara G.A.S. & Abeysekera W.P.K.M. (2020). Pharmacological Properties of Ceylon Cinnamon. In Cinnamon Botany, Agronomy, Chemistry, and Industrial Applications. Ranjith Senaratne & Ranjith Pathirana. Editors. Springer, Switzerland. PP 307-326.



Contact Details:
Dr.Sumudu Warnakulsuriya PhD
Director
S&T Business Centre
Industrial Technology Institute (CISIR)
363, Bauddaloka Mawatha
Colombo 7
Sri Lanka

Web: www.iti.lk Email: sumuduw@iti.lk

Telephone: 0094764800464